PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone Lymphoma

Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):252-259. doi: 10.1016/j.clml.2019.09.611. Epub 2019 Dec 9.


Background: The value of positron emission tomography/computed tomography (PET/CT) in the staging and assessment of treatment response in marginal zone lymphoma (MZL) lymphomas remains controversial. We investigated radiologic characteristics of subcutaneous MZL as imaged on PET/CT scans.

Patients and methods: From the records of a single medical center, for the years 2008 and 2017, we identified subcutaneous lesions in PET/CT scans of patients with histopathologically confirmed MZL in sites other than subcutaneous tissue.

Results: Of 571 scans of 178 patients, subcutaneous lesions were found in 20 (11%). Lesions were located in soft tissue structures, mainly along the lateral aspects of the buttocks, thighs and lower and upper back areas, the flank, and the shoulders. Median lengths of the long and short axes of the lesions were 2.0 (range, 1.1-6.0) cm and 0.8 (range, 0.3-2.0) cm, respectively. Median standardized maximum uptake value was 2.3 (range, 0.9-7.6). In 12 patients (60%), MZL was diagnosed at an early stage; 15 (75%) had lymph node involvement and 10 (50%) extranodal involvement. One had spleen and 2 had cutaneous involvement; none had gastric findings.

Conclusion: The findings of this study support the usefulness of PET/CT in the detection of subcutaneous MZL as well as in staging and treatment decisions.

Keywords: Extranodal; Imaging; Low-grade lymphoma; Mucosa-associated lymphoid tissue; Non-Hodgkin lymphoma.

MeSH terms

  • Adult
  • Aged
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage*
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / diagnostic imaging*
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography*
  • Retrospective Studies


  • Fluorodeoxyglucose F18